行情

VERU

VERU

VERU
NASDAQ

实时行情|Nasdaq Last Sale

1.890
-0.030
-1.56%
休市 16:00 11/15 EST
开盘
1.920
昨收
1.920
最高
1.940
最低
1.880
成交量
3.68万
成交额
--
52周最高
2.490
52周最低
1.180
市值
1.23亿
市盈率(TTM)
-6.6015
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

VERU 新闻

  • 马斯克:NASA付给波音载人航天费用太高 这不公平
  • 新浪科技.5小时前
  • 波音737客机又出事!飞行途中出现故障 紧急迫降
  • 海外网.6小时前
  • 约500万美国人有睡眠问题 手机可能是罪魁祸首
  • 新华国际.6小时前
  • 世界首富易主!比尔·盖茨反超亚马逊CEO贝佐斯登顶
  • 中国新闻网.6小时前

更多

所属板块

制药
+1.37%
制药与医学研究
+1.34%

热门股票

名称
价格
涨跌幅

VERU 简况

Veru Inc. is an oncology and urology biopharmaceutical company developing medicines for prostate cancer treatment and prostate cancer supportive care, as well as urology specialty pharmaceuticals. Its oncology drug candidates include VERU-111, an oral alpha and beta tubulin inhibitor, which is in a Phase 1b/2 study for the treatment of metastatic castration resistant prostate cancer; Zuclomiphene citrate, which is in a Phase II clinical trial for the treatment of hot flashes in men, and VERU-100, which is a gonadotropin-releasing hormone (GnRH) antagonist. Its urology specialty pharmaceutical drug candidate is Tadalafil and Finasteride Combination (TADFIN), which is a tadalafil and finasteride combination oral capsule for the treatment of men with benign prostatic hyperplasia. Its commercial products include the FC2 Female/Internal Condom for prevention of pregnancy and sexually transmitted infections, and PREBOOST wipes for the prevention of premature ejaculation.
展开

Webull提供Veru Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。